Table 1 Trial characteristics (design)
Characteristics, n (%) | HCQ | Steroid | Vit D | Total, n (%) |
|---|---|---|---|---|
192 | 108 | 57 | 357 | |
Study design info provided | 172 | 103 | 52 | 327 |
Parallel | 163 (94.8) | 99 (96) | 47 (90.4) | 309 (94.5) |
Factorial | 7 (4) | 2 (2) | 5 (9.6) | 14 (4.3) |
Other | 2 (1.2) | 2 (2) | 0 (0) | 4 (1.2) |
Phase of trial info provided | 182 | 95 | 43 | 320 |
Phase 0 or 1 | 4 (2.2) | 2 (2.1) | 1 (2.3) | 7 (2.2) |
Phase 2 or 1–2 | 59 (26.9) | 16 (16.8) | 11 (25.6) | 76 (23.8) |
Phase 3 or 2–3 | 93 (51.1) | 57 (60) | 20 (46.5) | 170 (53.1) |
Phase 4 or 3–4 | 36 (19.8) | 20 (21.1) | 11 (25.6) | 67 (20.9) |
Country info provided | 184 | 102 | 57 | 343 |
Multinational | 11 (6) | 7 (6.9) | 2 (3.5) | 20 (5.8) |
No. arms info provided | 192 | 108 | 57 | 357 |
> 2 randomised groups | 63 (32.8) | 15 (13.9) | 11 (19.3) | 89 (24.9) |
Control info provided | 192 | 108 | 57 | 357 |
Placebo control | 62 (32.3) | 15 (13.9) | 30 (52.6) | 107 (29.9) |
Primary sponsor info provided | 192 | 108 | 57 | 357 |
Academic | 52 (27.1) | 41 (38) | 22 (38.6) | 115 (32.2) |
Research institute | 18 (9.4) | 15 (13.9) | 8 (14) | 41 (11.5) |
Governmental | 13 (6.8) | 2 (1.8) | 3 (5.3) | 18 (5) |
Medical centre | 80 (41.6) | 35 (32.4) | 13 (22.8) | 128 (35.9) |
Pharmaceutical | 8 (4.2) | 4 (3.7) | 3 (5.3) | 15 (4.2) |
Other | 19 (9.9) | 10 (9.3) | 8 (14) | 37 (10.4) |
No sponsor | 2 (1) | 1 (0.9) | 0 (0) | 3 (0.8) |
Email contact info provided | 192 | 108 | 57 | 357 |
Email contact available | 98 (51) | 70 (64.8) | 36 (63.2) | 204 (57.1) |